LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01...

May 22
Last Trade: 1.71 0.00 0.00

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension...Read more


Satellos Bioscience Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with...

May 22
Last Trade: 0.66 0.00 0.00

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average...Read more


ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares...

May 22
Last Trade: 59.08 0.00 0.00

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the...Read more


Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study...

May 22
Last Trade: 8.47 0.00 0.00

Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by...Read more


Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

May 22
Last Trade: 2.42 0.00 0.00

GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that...Read more


UroGen Pharma Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent...

May 21
Last Trade: 4.18 0.00 0.00

PRINCETON, N.J. / May 21, 2025 / Business Wire / UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced the outcome of today’s meeting of the Oncologic Drugs Advisory...Read more


Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Acadia Pharmaceuticals 4.23 24.08 $21.80
Adaptive Biotechnologies 1.89 26.96 $8.91
Ascendis Pharma 1.39 0.88 $159.49
Abeona Therapeutics 0.66 11.54 $6.38
ABVC BioPharma 0.62 106.47 $1.20
Achieve Life Sciences 0.25 8.72 $3.06
Alector 0.11 8.40 $1.36
Alterity Therapeutics 0.10 2.49 $4.11
Atara Biotherapeutics 0.09 1.30 $6.99
Arvinas 0.08 1.28 $6.34
Aurinia Pharmaceuticals 0.07 0.84 $8.41
Aldeyra Therapeutics 0.07 2.93 $2.32
Akero Therapeutics 0.06 0.12 $48.42
BioCryst Pharmaceuticals 0.06 0.60 $10.13
Aprea Therapeutics 0.06 3.69 $1.66
Alzamend Neuro 0.05 1.39 $3.57
Adaptimmune Therapeutics 0.04 18.39 $0.28
Atai Life Sciences 0.04 2.15 $1.95

Highest Volume

 
CompanyVolumeLast Trade
Aptevo Therapeutics 2,169,399 $0.30
Alector 707,415 $1.36
Onconetix 689,716 $0.08
Applied Therapeutics 300,018 $0.39
Atai Life Sciences 271,872 $1.95
Autolus Therapeutics 249,160 $1.50
Akero Therapeutics 240,306 $48.42
Absci 217,029 $2.65
AbCellera Biologics 209,645 $1.95
Ardelyx 178,451 $3.95
Akebia Therapeutics 156,020 $2.83
Arvinas 155,825 $6.34
Candel Therapeutics 122,370 $5.44
Cabaletta Bio 119,954 $1.74
Aurinia Pharmaceuticals 111,413 $8.41
BioCryst Pharmaceuticals 109,778 $10.13
BioMarin Pharmaceutical 108,314 $58.07
Annexon 103,736 $2.00
Brainstorm Cell Therapeutics 99,823 $1.08
  • Upcoming FDA Catalysts

    • Arcutis Biotherapeutics (NASDAQ: ARQT) PDUFA Date

      May 22, 2025
    • UroGen Pharma (NASDAQ: URGN) PDUFA Date

      June 13, 2025
    • KalVista Pharmaceuticals (NASDAQ: KALV) PDUFA Date

      June 17, 2025
    • Merck (NYSE: MRK) PDUFA Date

      June 23, 2025
    • Regeneron Pharmaceuticals (NASDAQ: REGN) PDUFA Date

      July 10, 2025
    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      July 27, 2025

Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit